Serum interleukin-6 is associated with hypocalcemia, hypoferritinemia and hyperkalemia in end-stage renal disease patients

Submitted: 15 November 2022
Accepted: 30 December 2022
Published: 30 December 2022
Abstract Views: 1056
PDF: 290
HTML: 49
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Both of chronic inflammation and mineral disturbance are major concerns in patients with chronic kidney disease, particularly end-stage renal disease (ESRD). The present study aimed to investigate the association between circulating interleukin-6 (IL-6) and minerals dysregulation in patients diagnosed with ESRD and on a continuous hemodialysis regimen. This cross-sectional study included 74 patients undergoing continuous hemodialysis. Serum samples were tested for IL-6 using an enzyme-linked immunosorbent assay. Mineral were analyzed using an electrolyte analyzer and biochemical tests. Parameter correlations were analyzed using the Pearson’s correlation test. Among the studies group, the male: female ratio was 1:0.72. IL-6 mean value was 13.77 pg/mL ±9.79 SD. IL-6 was significantly negatively correlated with circulating iron and calcium levels (r= –0.229, P=0.049; r= –0.252, P=0.03, respectively). IL-6 was significantly positively correlated with K+ levels (r=0.269, P=0.02). The present study highlighted the substantial role of IL-6 in mineral dysregulation in hemodialysis patients. However, identifying IL-6 as potential therapeutic target for minimizing and monitoring clinical effects of mineral disturbances in hemodialysis patients still requires further confirmatory studies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol Dial Transplant 2018;33:iii35-40.
Globa-Brzozka A, Franczyk B, Olszweski R, Rysz J. The influence of inflammation on anemia in CKD patients. Int J Mol Sci 2020;21(3).
Meijers B, Farré R, Dejongh S, et al. Intestinal barrier function in chronic kidney disease. Toxins (Basel) 2018;10:1-11.
Martinez L, Perla M, Tabbara M, et al. Systemic profile of cytokines in arteriovenous fistula patients and their associations with maturation failure. Kidney 2022;3:677-86.
Heaf J, Heiro M, Petersons A, et al. Suboptimal dialysis initiation is associated with comorbidities and uraemia progression rate but not with estimated glomerular filtration rate. Clin Kidney J 2021;14:933-42.
Molla MD, Degef M, Bekele A, et al. Assessment of serum electrolytes and kidney function test for screening of chronic kidney disease among Ethiopian Public Health Institute staff members, Addis Ababa, Ethiopia. BMC Nephrol 2020;21:1-11.
Gutiérrez OM. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Reports 2021;6:2261-9.
Nakamura K, Hayashi H, Kubokawa M. Proinflammatory cytokines and potassium channels in the kidney. Mediat Inflamm 2015;2015.
Goldner W. Cancer-related hypercalcemia. J Oncol Pract 2016;12:426-32.
Molinari P, Alfieri CM, Mattinzoli D, et al. Bone and mineral disorder in renal transplant patients: overview of pathology, clinical, and therapeutic aspects. Front Med 2022;9:1-11.
Wu SC, Liang CX, Zhang YL, Hu WP. Elevated serum procalcitonin level in patients with chronic kidney disease without infection: a case-control study. J Clin Lab Anal 2020;34:1-7.
Cantero-Navarro E, Rayego-Mateos S, Orejudo M,set al. Role of macrophages and related cytokines in kidney disease. Front Med 2021;8:1-18.
Yacoub MF, Ferwiz HF, Said F. Effect of interleukin and hepcidin in anemia of chronic diseases. Anemia 2020;2020.
Bandach I, Segev Y, Landau D. Experimental modulation of Interleukin 1 shows its key role in chronic kidney disease progression and anemia. Sci Rep 2021;11:1-14.
Varga E, Pap R, Jánosa G, et al. IL-6 regulates hepcidin expression via the BMP/SMAD pathway by altering BMP6, TMPRSS6 and TfR2 expressions at normal and inflammatory conditions in BV2 microglia. Neurochem Res 2021;46:1224-38.
Portales-Castillo I, Simic P. PTH, FGF-23, Klotho and Vitamin D as regulators of calcium and phosphorus: genetics, epigenetics and beyond. Front Endocrinol (Lausanne) 2022;13:1-12.
Hanna RM, Ahdoot RS, Kalantar-Zadeh K, et al. Calcium transport in the kidney and disease processes. Front Endocrinol (Lausanne) 2022;12:1-11.
Haidar O, O’Neill N, Staunton CA, et al. Pro-inflammatory cytokines drive deregulation of potassium channel expression in primary synovial fibroblasts. Front Physiol 2020;11:1-13.
Abramowitz LK, Hanover JA. Chronically elevated O-GlcNAcylation limits nitric oxide production and deregulates specific pro-inflammatory cytokines. Front Immunol 2022;13:1-9.
Udensi K, Tchounwou P. Potassium homeostasis, oxidative stress, and human disease. Int J Clin Exp Physiol 2017;4:111-23.

How to Cite

Alubaidi, G. T., Humadi , Y. A., Hamoodi, D. A., Mahdi , H. T., Anid, B. A., Jasim, I. A., & Abdalfatah, I. M. (2022). Serum interleukin-6 is associated with hypocalcemia, hypoferritinemia and hyperkalemia in end-stage renal disease patients. Italian Journal of Medicine, 16(1). https://doi.org/10.4081/itjm.2022.1550